[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jaseng Medical Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":183},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,77,101,124,142,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100602702","pilot-study-clinical-trial-of-ultrasound-guiding-pharmacopuncture-therapy-for-acute-low-back-pain-100602702",false,"NCT07126951","Pilot Study: Clinical Trial of Ultrasound Guiding Pharmacopuncture Therapy for Acute Low Back Pain","A Pragmatic Randomized Controlled Pilot Clinical Trial of Ultrasound Guiding Pharmacopuncture Therapy for Acute Low Back Pain Following Traffic Accidents","Inclusion Criteria:\n\nParticipants must meet all of the following:\n\nAdults aged 19 to 70 years.\n\nPatients who developed acute low back pain within 7 days after a traffic accident.\n\nNumeric Rating Scale (NRS) score of 5 or higher for low back pain.\n\nRadiological evidence of disc narrowing on lumbar spine X-ray.\n\nComplaints of radiating leg pain.\n\nHospitalized for treatment related to the traffic accident.\n\nAble and willing to provide written informed consent voluntarily.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following:\n\nDiagnosed with serious underlying conditions causing back pain (e.g., malignancy, spinal infection, inflammatory spondylitis).\n\nPresence of progressive or severe neurological deficits.\n\nUnderwent lumbar surgery or procedures within the past 3 weeks.\n\nBack pain caused by non-spinal soft tissue disorders (e.g., fibromyalgia, rheumatoid arthritis, gout).\n\nPresence of chronic conditions that could interfere with study results (e.g., cardiovascular disease, renal disease, diabetic neuropathy, dementia, epilepsy).\n\nTaking medications that could affect study outcomes (e.g., steroids, immunosuppressants, psychiatric drugs).\n\nContraindicated or unsafe for acupuncture (e.g., bleeding disorders, anticoagulant therapy, severe diabetes with infection risk, severe cardiovascular conditions).\n\nCurrently pregnant or planning pregnancy.\n\nDiagnosed with severe mental illness.\n\nParticipation in other clinical trials (excluding observational studies).\n\nUnable to properly complete the informed consent form.\n\nDeemed inappropriate for participation by the investigator for any other reason.","ALL","19 Years","70 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot randomized controlled clinical trial aims to evaluate the effectiveness and safety of ultrasound-guided deep pharmacopuncture therapy for acute low back pain (LBP) that occurs within seven days following a traffic accident. While traditional Korean medicine-including acupuncture, herbal medicine, pharmacopuncture, and Chuna manual therapy-is commonly used for post-accident injuries, few studies have focused on deep pharmacopuncture administered under ultrasound guidance. This study will provide preliminary evidence to assess whether ultrasound-guided techniques offer added clinical benefits.\n\nA total of 40 patients hospitalized at Jaseng Hospital of Korean Medicine in Haeundae, Korea, will be recruited and randomly assigned into two groups: the intervention group will receive integrative Korean medicine therapy plus ultrasound-guided pharmacopuncture, while the control group will receive integrative Korean medicine therapy alone. Both groups will undergo treatment during hospitalization, with the pharmacopuncture administered up to three times between hospital day 2 and day 4 in the intervention group. Baseline assessment will be done on day 2 before treatment, and the primary outcome will be measured on day 5. Follow-up assessments will be conducted at 2 and 4 weeks via telephone.\n\nThe primary outcome is the change in low back pain intensity as measured by the Numeric Rating Scale (NRS). Secondary outcomes include radiating pain, lumbar range of motion, Oswestry Disability Index (ODI), EQ-5D for quality of life, and the Patient Global Impression of Change (PGIC). Adverse events will also be monitored and classified according to established safety criteria.\n\nThis study will utilize both intention-to-treat (ITT) and per-protocol (PP) analyses, with linear mixed models and multiple imputation used to address missing data. Given the limited existing evidence on ultrasound-guided deep pharmacopuncture, this trial is designed to explore its feasibility and provide the groundwork for future large-scale trials.\n\nParticipants will be selected based on strict inclusion and exclusion criteria to ensure safety and consistency. Ethical standards including informed consent, data privacy, and ongoing safety monitoring will be rigorously upheld throughout the study.",[27],"Low Back Pain (LBP)",[29,30],"pharmacopuncture","Ultrasound Guiding","NOT_YET_RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":21},"2026-09-01",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Jaseng Medical Foundation","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":76},"100634746","safety-and-effectiveness-of-ultrasound-guided-pharmacopuncture-for-spinal-diseases-100634746","NCT07543692","Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases","Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases: A Multi-center, Registry Study","Inclusion Criteria:\n\n1. Patients diagnosed with spinal diseases (KCD codes M and S).\n2. Patients whose Numeric Rating Scale (NRS) score for the most predominant pain (neck pain with upper limb radiating pain OR low back pain with lower limb radiating pain) caused by spinal diseases is 5 or higher.\n3. Outpatients or inpatients scheduled to utilize an ultrasound scan during pharmacopuncture (the decision to perform ultrasound-guided pharmacopuncture is made according to the clinician's routine medical judgment, not for research purposes).\n4. Patients who voluntarily agree to participate in the clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have difficulty completing the written informed consent form.\n2. Women who are pregnant, planning to become pregnant, or breastfeeding.\n3. Patients deemed inappropriate for study participation by the investigator due to severe underlying diseases (e.g., cancer or other malignant neoplasms) that may interfere with treatment effects or result interpretation.\n4. Individuals who are deemed unsuitable for participation in the clinical study by the researcher.","69 Years",{"count":53,"type":21},600,"8 Weeks","OBSERVATIONAL","This multi-center registry study aims to evaluate the safety and effectiveness of ultrasound-guided pharmacopuncture for patients diagnosed with spinal diseases. A total of 600 patients, aged 19 to under 70 years, will be enrolled across six Korean medicine hospitals. Eligible participants must have a pain Numeric Rating Scale (NRS) of 5 or higher for their most dominant spinal pain, which includes neck pain with upper extremity radiating pain, or low back pain with lower extremity radiating pain. As a non-interventional observational study, it will include patients who are already planned to receive ultrasound-guided pharmacopuncture as part of their routine clinical care. The primary outcome is the change in the most dominant spinal pain intensity measured by the NRS from baseline to 4 weeks. Secondary outcomes include functional disability evaluated using the Neck Disability Index (NDI) or Oswestry Disability Index (ODI), quality of life using the EQ-5D-5L, and patient satisfaction. Safety will be closely monitored by assessing all adverse events at every visit, evaluating their incidence, severity, and causality related to the procedure. Participants will be selected based on strict inclusion and exclusion criteria to ensure safety and consistency. Ethical standards including informed consent, data privacy, and ongoing safety monitoring will be rigorously upheld throughout the study.",[58,59,60,61],"Spinal Disease","Neck Pain","Low Back Pain","Radiculopathy",[63,64,65,66,67,68],"Pharmacopuncture","Ultrasound-guided","Registry","Observational Study","Korean Medicine","Spinal Pain","2026-04-27",{"date":71,"type":35},"2026-05-01",{"date":73,"type":21},"2026-04-28",{"date":39,"type":21},{"name":41,"class":42},6,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100607344","the-efficacy-and-safety-of-shoulder-motion-style-acupuncture-treatment-msat-on-in-patients-with-shoulder-pain-caused-by-traffic-accidents-100607344","NCT07187336","The Efficacy and Safety of Shoulder Motion Style Acupuncture Treatment (MSAT) on in Patients With Shoulder Pain Caused by Traffic Accidents","The Efficacy and Safety of Shoulder Motion Style Acupuncture Treatment (MSAT) on in Patients With Shoulder Pain Caused by Traffic Accidents: A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\nAdults aged 19 to 70 years\n\nHospitalized with shoulder pain within 5 days after a traffic accident\n\nShoulder pain intensity ≥ 5 on the Numeric Rating Scale (NRS) with observed limitation of movement\n\nAble and willing to provide written informed consent\n\nExclusion Criteria:\n\nSerious conditions causing shoulder pain (e.g., malignant tumor, infection)\n\nProgressive or severe neurological deficits\n\nRecent shoulder surgery or procedure within 3 weeks\n\nShoulder pain mainly due to non-shoulder disorders (e.g., fibromyalgia, rheumatoid arthritis, gout)\n\nContraindications to MSAT (e.g., fracture, dislocation, ligament rupture or instability, severe inflammation)\n\nChronic diseases interfering with assessment (e.g., cardiovascular disease, renal disease, diabetic neuropathy, dementia, epilepsy)\n\nCurrent use of steroids, immunosuppressants, psychiatric drugs, or other medications that may affect results\n\nContraindications to acupuncture (e.g., bleeding disorders, anticoagulant use, severe diabetes, severe cardiovascular disease)\n\nPregnant or planning pregnancy\n\nSevere psychiatric illness\n\nParticipation in another interventional clinical trial\n\nUnable to provide informed consent\n\nAny other condition deemed inappropriate by the investigator",{"count":85,"type":21},98,[24],"This study will test the effectiveness and safety of Motion Style Acupuncture Treatment (MSAT) for shoulder pain caused by traffic accidents. About 98 hospitalized patients with acute shoulder pain after a traffic accident will take part.\n\nParticipants will be randomly assigned to one of two groups:\n\nMSAT + integrative Korean medicine group (acupuncture, herbal medicine, pharmacopuncture, Chuna therapy, plus MSAT), or\n\nIntegrative Korean medicine only group (acupuncture, herbal medicine, pharmacopuncture, Chuna therapy).\n\nMSAT involves inserting needles into the shoulder area and gently moving the joint to improve pain relief and mobility. All treatments used in this study are standard care in Korean medicine.\n\nThe main outcomes are pain reduction, shoulder movement, daily function, quality of life, and patient satisfaction. Safety will also be monitored by recording any side effects such as temporary soreness, bruising, or discomfort.\n\nTreatment will be provided during hospitalization (up to 5 days), and patients will be followed up by phone at 2 weeks and 1 month after enrollment.\n\nThe results of this trial will help determine whether adding MSAT to standard integrative Korean medicine treatment provides greater benefit for patients with acute shoulder pain after traffic accidents.",[89],"Shoulder Pain",[91],"motion style acupuncture treatment","RECRUITING","2026-03-05",{"date":95,"type":35},"2026-03-09",{"date":97,"type":35},"2025-11-02",{"date":99,"type":21},"2026-09-30",{"name":41,"class":42},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100616320","clinical-research-on-the-comparative-effectiveness-and-safety-of-jhg002-therapy-for-chronic-low-back-pain-a-multicenter-randomized-controlled-trial-100616320","NCT07304076","Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 to 69 years at the time of signing the informed consent.\n* Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.\n* Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.\n* Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.\n\nExclusion Criteria:\n\n* Patients diagnosed with serious underlying conditions that may cause low back pain, such as spinal metastasis of malignancy, acute vertebral fracture, or spinal dislocation.\n* Patients with progressive neurological deficits or those presenting with severe neurological symptoms.\n* Patients whose pain originates from non-spinal soft tissue disorders, including tumors, fibromyalgia, rheumatoid arthritis, or gout.\n* Individuals with other chronic medical conditions that may interfere with treatment response or interpretation of study outcomes, such as stroke, myocardial infarction, chronic kidney disease, diabetic neuropathy, dementia, or epilepsy.\n* Individuals currently taking corticosteroids, immunosuppressants, psychiatric medications, or any other drugs that may influence study results.\\*\n* Patients for whom pharmacopuncture is inappropriate or unsafe, including those with bleeding disorders or those receiving anticoagulant therapy.\n* Individuals who have taken analgesic medications such as NSAIDs or received pharmacopuncture treatment within the past 1 week.\n* Women of childbearing potential who are unwilling to use medically acceptable contraception (e.g., surgical sterilization, intrauterine device, condom or diaphragm use, injectable or implantable contraceptives) throughout the study period.\n* Pregnant or breastfeeding women.\n* Individuals with a history of hypersensitivity or allergic reactions to Hominis placenta pharmacopuncture (JHG002).\n* Patients with uncontrolled diabetes mellitus (fasting blood glucose ≥ 180 mg\u002FdL).\n* Individuals whose AST (GOT) or ALT (GPT) levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Individuals whose serum creatinine levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Patients suspected of having an underlying organic disease.\n* Patients with moderate systemic complications involving organs other than the heart, liver, or kidneys.\n* Patients with psychogenic disorders.\n* Individuals with an implanted cardiac pacemaker.\n* Patients with inflammation, infection, wounds, or other lesions at the planned pharmacopuncture sites that would prevent safe administration.\n* Patients within 3 months after lumbar spine surgery.\n* Individuals who have participated in another clinical trial within the past 1 month, or who plan to participate in another clinical trial-including follow-up periods-within 6 months from the screening date.\n* Any individual deemed unsuitable for participation in this study by the investigator.",{"count":108,"type":21},96,[24],"A multicenter randomized controlled trial",[112],"Chronic Low Back Pain (CLBP)",[114,29],"chronic low back pain","2026-02-24",{"date":117,"type":35},"2026-02-25",{"date":119,"type":35},"2025-12-17",{"date":121,"type":21},"2029-11-28",{"name":41,"class":42},4,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":131,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":43},"100432025","the-effectiveness-and-safety-of-integrative-korean-medicine-treatment-for-bells-palsy-100432025","NCT04905745","The Effectiveness and Safety of Integrative Korean Medicine Treatment for Bell's Palsy","The Effectiveness and Safety of Integrative Korean Medicine Treatment for Bell's Palsy : A Prospective Observational Preliminary Study","Inclusion Criteria:\n\n1. age of 19 to 69\n2. diagnosed with unilateral peripheral facial nerve palsy\n3. onset of facial palsy within 3 weeks or less.\n4. an individual who can provide written consent form to participate in the study.\n\nExclusion Criteria:\n\n1. diagnosed with central nervous system disease causing facial palsy\n2. secondary facial palsy after multiple sclerosis, tumor, cerebrovascular disease and temporal bone fracture.\n3. Ramsay-Hunt syndrome\n4. bilateral or recurrent facial nerve palsy.\n5. an individual who received any treatment that can have a significant effect on changes in facial paralysis within recent 2 month. (ie. facial nerve decompression surgery)\n6. already or planned to be pregnant or breast-feeding within the study period.\n7. uncontrolled diabetes mellitus within the last 3 months.\n8. within a month after participating any other facial palsy-related clinical trials, or planning to participate other clinical trials within 6 month.\n9. impossible to read and understand the documents, regarding informed consent form and the questionnaires.\n10. difficult to participate according to the judgement of researchers.",{"count":132,"type":21},100,"This is an observational study that evaluate the effectiveness and safety of Korean integrative treatments in patients with peripheral facial nerve palsy. Adulthood patients aged between 19 to 69 who were diagnosed with peripheral facial nerve palsy and receive Korean integrative treatments for facial palsy will be enrolled in the study and the change will be followed according to the Facial disability index (FDI) at the 3 month moment after baseline.",[135],"Facial Paralysis, Peripheral",{"date":117,"type":35},{"date":138,"type":35},"2021-05-25",{"date":140,"type":21},"2027-08-31",{"name":41,"class":42},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100587712","the-effectiveness-and-safety-of-pharmacopuncture-on-inpatients-with-acute-knee-pain-caused-by-traffic-accidents-100587712","NCT06931951","The Effectiveness and Safety of Pharmacopuncture on Inpatients With Acute Knee Pain Caused by Traffic Accidents","The Effectiveness and Safety of Pharmacopuncture on Inpatients With Acute Knee Pain Caused by Traffic Accidents : A Pragmatic Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* When the NRS (Numeric Rating Scale) of knee pain caused by a traffic accident is 5 or higher.\n* Patients hospitalized for traffic accident treatment.\n* Patients with acute pain within 14 days of experiencing knee pain due to a traffic accident.\n* Patients aged between 19 and 70 years old.\n* participants who agree to participate in clinical research and provide written test subject consent.\n\nExclusion Criteria:\n\n* For patients diagnosed with a specific serious disease that may cause knee pain (acute fracture, dislocation, complete rupture of ligaments, etc.)\n* If the cause of the pain is caused by a disease other than the knee (tumor, fibromyalgia, rheumatoid arthritis, gout, lumbar disc herniation, etc.)\n* Cases where surgical intervention is required due to suspected acute fracture, dislocation, or ligament and cartilage damage\n* If there is another acute disease (stroke, myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy, etc.) that may interfere with the treatment effect or interpretation of results\n* Patients currently taking steroids, immunosuppressants, mental illness drugs, or other drugs that may affect their findings\n* Inadequate or unsafe medication: hemorrhagic disease, anticoagulant therapy, severe diabetic patients with risk of infection\n* Patients who have taken drugs that may affect pain, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), or have received herbal acupuncture or physical therapy within the past week\n* In the case of pregnant women and in the case of planning to become pregnant or nursing\n* Patients within 3 months after knee surgery or if knee replacement surgery was performed\n* If it has been less than 1 month since participants finished participating in another clinical study, or if participants are planning to participate in another clinical study during the study participation and follow-up period within 6 months from the date of selection\n* If it is difficult to fill out the consent form for research participation\n* In cases where it is difficult for other researchers to participate in clinical research",{"count":20,"type":21},[24],"The purpose of this study is to reveal the effectiveness and safety of knee herbal acupuncture for patients with acute knee joint pain caused by a traffic accident. It is a practical clinical study to confirm the comparative effectiveness by comparing the strategy of treating knee herbal acupuncture in parallel with the strategy of treating it with integrated oriental medicine treatment, which is an existing treatment method.",[153],"Pharmacologic Action","2026-01-13",{"date":156,"type":35},"2026-01-15",{"date":158,"type":35},"2025-05-22",{"date":160,"type":21},"2026-12-31",{"name":41,"class":42},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":123},"100517970","non-pharmacological-treatment-vs-pharmacological-treatment-for-non-acute-lumbar-disc-herniation-100517970","NCT06024460","Non-pharmacological Treatment vs Pharmacological Treatment for Non-acute Lumbar Disc Herniation","Comparative Effectiveness of Non-pharmacological Treatment and Pharmacological Treatment for Non-acute Lumbar Disc Herniation: a Multi-centered, Pragmatic Randomized Controlled, Parallel-grouped Study","Inclusion Criteria:\n\n* aged 19 to 69 years.\n* lower back pain that has persisted for at least 1 month.\n* a Numeric Rating Scale (NRS) score of 5 or higher for either lower back pain or radiating leg pain over the past three consecutive days.\n* confirmed lumbar disc herniation on MRI that can explain the lower back pain.\n* who have provided written informed consent and agreed to participate in the clinical study.\n\nExclusion Criteria:\n\n* diagnosed with specific severe diseases that could be the cause of lower back pain or leg pain (e.g., spinal metastasis, acute fractures, and spinal dislocation).\n* showing progressive neurological deficits or severe neurological symptoms.\n* with pain originating from soft tissue disorders other than the spine (e.g., tumors, fibromyalgia, rheumatoid arthritis, gout).\n* with other chronic conditions (e.g., stroke and myocardial infarction, renal disease, diabetic neuropathy, dementia, epilepsy) that may interfere with the treatment effect or result interpretation.\n* taking steroids, immunosuppressive drugs, psychiatric medications, or other medications that may impact the study results.\n* acupuncture or nerve block treatment is inappropriate or unsafe, such as those with a history of bleeding disorders, receiving anticoagulant therapy, or diagnosed with uncontrolled diabetes.\n* taken non-steroidal anti-inflammatory drugs (NSAIDs) or other pain-affecting drugs or received acupuncture treatment within the past 5 days.\n* Pregnant women, those planning pregnancy, or breastfeeding women.\n* within 3 months after lumbar surgery.\n* who have not completed participation in another clinical study within the past month or have plans to participate in another clinical study within 6 months from the selection date or during the study participation and follow-up period.\n\nInability to provide written informed consent.\n\n\\- Other cases where the researchers determine that participation in the clinical study would be difficult.",{"count":170,"type":21},200,[24],"This is a randomized controlled study comparing non-pharmacological treatment to proactive pharmacological treatment for patient with non-acute lumbar disc herniation with moderate or higher levels of pain. The study involves 200 adult patients aged 19-69, with 50 patients from each participating hospital. Patients will be randomly assigned to either the non-pharmacological treatment group or the pharmacological treatment group 1:1 ratio. Specific interventions will be determined by doctors and Korean medicine doctors without predefined treatment strategies. The non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy and motion style acupuncture. The pharmacological treatment include medication prescription, injection, and nerve block. Treatment period is 8 weeks, and f\u002Fu for 3 years.",[174],"Lumbar Disc Herniation","2025-09-09",{"date":177,"type":35},"2025-09-11",{"date":179,"type":35},"2023-08-09",{"date":181,"type":21},"2030-12-31",{"name":41,"class":42},""]